Prostanoid production and pulmonary hypertension after fat embolism are not modified by methylprednisolone.
Bilateral cemented arthroplasty (BCA) in anaesthetized mongrel dogs produces particulate fat and marrow embolism of the lung. Methylprednisolone sodium succinate (MPSS) has been advocated for post-traumatic fat embolism to prevent acute lung injury. We used the BCA procedure to produce acute fat and marrow embolism, and tested the efficacy of MPSS (30 mg.kg-1) in preventing physiological and pathological markers of acute lung injury. Dogs (n = 6) pre-treated with MPSS demonstrated similar acute increases in pulmonary artery pressure (PAP) within one minute of BCA (17.8 +/- 7.3 mmHg) as the untreated (control n = 7) dogs (18.6 +/- 12.6). Pulmonary vascular resistance (PVR) increased to the same degree in both groups (455 +/- 323 and 319 +/- 137 dyne.sec.cm-5) and PaO2 decreased by 18.3 +/- 6.4 mmHg in the control group as opposed to 12.4 +/- 7.7 mmHg in the MPSS group within five minutes of BCA. Circulating arterial and mixed venous plasma concentrations of thromboxane B2 (TxB2) increased within one minute of BCA in both groups with no increase in the transpulmonary gradient. Arterial plasma 6-keto prostaglandin F1 alpha (6-keto PGF1 alpha) increased (0.91 +/- 0.29 ng.ml-1 and 0.87 +/- 0.43 ng.ml-1) in both groups one minute after BCA. Mixed venous 6-keto PGF1 alpha plasma concentration also increased, but a significant transpulmonary 6-keto PGF1 alpha gradient was found.(ABSTRACT TRUNCATED AT 250 WORDS)
Byrick
R J
RJ
Department of Anaesthesia, St. Michael's Hospital.
Mullen
J B
JB
Wong
P Y
PY
Kay
J C
JC
Wigglesworth
D
D
Doran
R J
RJ
D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis* / Q000097:blood; D000818:Animals; D001794:Blood Pressure / Q000502:physiology; D001843:Bone Cements / Q000627:therapeutic use; D001853:Bone Marrow; D004285:Dogs; D004620:Embolism, Fat / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D005269:Femur / Q000601:surgery; D006622:Hip Prosthesis / Q000009:adverse effects; D006976:Hypertension, Pulmonary / Q000209:etiology / Q000503:physiopathology*; D008168:Lung / Q000473:pathology; D008775:Methylprednisolone / Q000494:pharmacology*; D010100:Oxygen / Q000097:blood; D011651:Pulmonary Artery; D011655:Pulmonary Embolism / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D013929:Thromboxane B2 / Q000096:biosynthesis* / Q000097:blood; D013997:Time Factors; D014655:Vascular Resistance / Q000502:physiology
D001843:Bone Cements; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D010100:Oxygen; D008775:Methylprednisolone